Compare · AKUS vs SBTX

AKUS vs SBTX

Side-by-side comparison of Akouos Inc. (AKUS) and Silverback Therapeutics Inc. (SBTX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both AKUS and SBTX operate in Specialty Chemicals (Consumer Discretionary), so they compete in similar markets.
  • SBTX has more recent analyst coverage (6 ratings vs 1 for AKUS).
MetricAKUSSBTX
Company
Akouos Inc.
Silverback Therapeutics Inc.
Price
-
-
Market cap
-
-
1M return
-
-
1Y return
-
-
Industry
Specialty Chemicals
Specialty Chemicals
Exchange
NASDAQ
NASDAQ
IPO
2020
2020
News (4w)
0
0
Recent ratings
1
6
AKUS

Akouos Inc.

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. Akouos, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

SBTX

Silverback Therapeutics Inc.

Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.